|
Notice of Annual and Special Meeting on September 30th 2015
|
4
|
Resverlogix Corp.
|
Jul 20, 2015 05:33PM
|
|
Notice of Meeting and Information Circular on SEDAR
|
5
|
Resverlogix Corp.
|
Aug 11, 2018 11:19AM
|
|
Notice of Meeting and Information Circular on SEDAR
|
4
|
Zenith Epigenetics
|
Aug 11, 2018 11:34AM
|
|
Notice of Meeting and Management Information Circular Posted
|
4
|
Zenith Epigenetics
|
Sep 28, 2019 07:52AM
|
|
Notice of Meeting and Management Information Circular Posted
|
2
|
Resverlogix Corp.
|
Sep 26, 2019 08:26PM
|
|
Novartis Phase III study shows Canakinumab reduces MACE events
|
5
|
Resverlogix Corp.
|
Jun 22, 2017 11:19AM
|
|
Novel approaches to targeting BRD4
|
4
|
Zenith Epigenetics
|
Dec 14, 2017 11:24AM
|
|
November 8, 2016, Resverlogix presented at BIO Europe in Cologne, Germany.
|
1
|
Resverlogix Corp.
|
Nov 09, 2016 05:11PM
|
|
November conferences
|
4
|
Resverlogix Corp.
|
Oct 15, 2015 12:08PM
|
|
Now a Phase 2 trial
|
5
|
Zenith Epigenetics
|
Feb 16, 2018 04:33PM
|
|
Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
4
|
Resverlogix Corp.
|
Aug 10, 2019 12:14PM
|
|
Now recruiting: ZEN-3694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)
|
6
|
Zenith Epigenetics
|
May 06, 2019 03:19PM
|
|
Now the webcast is up
|
2
|
Resverlogix Corp.
|
Mar 11, 2019 01:24PM
|
|
Nuevolution and bromodomain selective BET inhibitors
|
3
|
Zenith Epigenetics
|
Nov 27, 2017 12:54PM
|
|
Nuevolution and bromodomain selective BET inhibitors
|
3
|
Resverlogix Corp.
|
Nov 27, 2017 12:55PM
|
|
NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
1
|
Zenith Epigenetics
|
Jul 07, 2016 07:31PM
|
|
NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
5
|
Resverlogix Corp.
|
Jul 07, 2016 07:28PM
|
|
NYAS Symposium on April 28th
|
3
|
Zenith Epigenetics
|
Apr 27, 2016 03:04PM
|
|
NYC events
|
5
|
Resverlogix Corp.
|
Aug 31, 2018 03:21PM
|
|
ODYSSEY and Anti-histamines
|
7
|
Resverlogix Corp.
|
Mar 11, 2018 10:33AM
|
